FIELD: chemistry.
SUBSTANCE: present invention relates to use of antibody-drug conjugate (ADC) of formula II for treating solid human tumors expressing HER2, where the solid human tumor expressing HER2 represents endometrial cancer, particularly serous endometrial carcinoma (USC). In particular, the present invention refers to ADC containing duocarmicin used for treating endometrial cancer, namely, where endometrial cancer is HER2 IHC 2+ or 1+, as well as HER2 FISH-negative.
EFFECT: treating solid human tumors expressing HER2.
4 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | 2015 |
|
RU2670157C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
